相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Series: Implications of the recent CVOTs in type 2 diabetes Impact on guidelines: The endocrinologist point of view
Andre J. Scheen
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7% Results From the CREDENCE Trial
Christopher P. Cannon et al.
CIRCULATION (2020)
Challenging 2019 ESC guidelines for the management of type 2 diabetes
A. J. Scheen
DIABETES & METABOLISM (2020)
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
Erik J. M. van Bommel et al.
KIDNEY INTERNATIONAL (2020)
Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Andre J. Scheen
EXPERT OPINION ON DRUG SAFETY (2020)
Renal physiology of glucose handling and therapeutic implications
David Z. Cherney et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Claire C. J. Dekkers et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Hiddo J. L. Heerspink et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the Cardiac Benefits of Empagliflozin Independent of its Hypoglycemic Activity?
Carlos G. Santos-Gallego et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
Tadashi Toyama et al.
DIABETES OBESITY & METABOLISM (2019)
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Pantelis Sarafidis et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus ana Stage 3a/3b CKD
Andrew S. Allegretti et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
Masako Saito et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
An update on the safety of SGLT2 inhibitors
Andre J. Scheen
EXPERT OPINION ON DRUG SAFETY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Jaime A. Davidson
POSTGRADUATE MEDICINE (2019)
Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
Kengo Kidokoro et al.
CIRCULATION (2019)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2019)
Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations
Chaicharn Deerochanawong et al.
DIABETES OBESITY & METABOLISM (2019)
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial
Milton Packer et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Carol Pollock et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Update on the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in Asians and non-Asians
Yoshihito Fujita et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendan L. Neuen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
Jiahua Li et al.
CLINICAL KIDNEY JOURNAL (2019)
Treatment response between Asian and non-Asian patients with type 2 diabetes: is there any similarity or difference?
Xiao-Ling Cai et al.
CHINESE MEDICAL JOURNAL (2019)
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
A. J. Scheen
DIABETES & METABOLISM (2019)
Why not adding a glucose- lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin?
Andre J. Scheen
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Preventing and treating kidney disease in patients with type 2 diabetes
Pierre Delanaye et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Michael S. Kelly et al.
POSTGRADUATE MEDICINE (2019)
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOMEA® trial
Takashi Kadowaki et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus
Sachiya Ikeda et al.
DRUG RESEARCH (2019)
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
George Grunberger et al.
DIABETES THERAPY (2018)
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
George Grunberger et al.
DIABETES THERAPY (2018)
SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review
Radica Z. Alicic et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Eduardo Flores et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
Brendon L. Neuen et al.
CIRCULATION (2018)
SGLT2 inhibition and kidney protection
Josselin Nespoux et al.
CLINICAL SCIENCE (2018)
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Claire C. J. Dekkers et al.
CURRENT DIABETES REPORTS (2018)
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
Paola Fioretto et al.
DIABETES OBESITY & METABOLISM (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2018)
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease (gfx350, 2018)
Claire C. J. Dekkers et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
Silvio E. Inzucchi et al.
CIRCULATION (2018)
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETOLOGIA (2018)
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
Alvaro Garcia-Ropero et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
Yoshishige Samukawa et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
Harindra Rajasekeran et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
William G. Herrington et al.
CLINICAL KIDNEY JOURNAL (2018)
No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis
Xiaoling Cai et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A. DeFronzo et al.
NATURE REVIEWS NEPHROLOGY (2017)
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
V. Sahasrabudhe et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype
Lee Ling Lim et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Management of patients with diabetes and CKD: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Vlado Perkovic et al.
KIDNEY INTERNATIONAL (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease
Ronan Roussel et al.
ADVANCES IN THERAPY (2015)
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2015)
Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor
Damayanthi Devineni et al.
CLINICAL THERAPEUTICS (2015)
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study
A. Kashiwagi et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Katherine R. Tuttle et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
Hala Yamout et al.
AMERICAN JOURNAL OF NEPHROLOGY (2014)
Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
Nobuya Inagaki et al.
CLINICAL DRUG INVESTIGATION (2014)
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes Mellitus
Akiko Sarashina et al.
CLINICAL THERAPEUTICS (2014)
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
S. Macha et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
J. -F. Yale et al.
DIABETES OBESITY & METABOLISM (2014)
Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
Sreeneeranj Kasichayanula et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Renal Glucose Handling Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
Ele Ferrannini et al.
DIABETES CARE (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
分享论文
